Current knowledge and trends in age-related macular degeneration: Today's and future treatments

Retina

Volumn 33, Issue 8, 2013, Pages 1487-1502

  Velez Montoya, Raul ^a   Oliver, Scott C N ^a   Olson, Jeffrey L ^a   Fine, Stuart L ^a   Mandava, Naresh ^a   Quiroz Mercado, Hugo ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

aflibercept; age related macular degeneration; antipericyte therapy; bevacizumab; choroidal neovascular membrane; combined therapy; geographic atrophy; ranibizumab

Indexed keywords

AL 8309A; ARC 1905; BEVACIZUMAB; CILIARY NEUROTROPHIC FACTOR; COMPLEMENT FACTOR H; CORTICOSTEROID; ECULIZUMAB; FENRETINIDE; FLUOCINOLONE ACETONIDE; ISOTRETINOIN; LIPOFUSCIN; PLATELET DERIVED GROWTH FACTOR; PROSTAGLANDIN E1; RANIBIZUMAB; RAPAMYCIN; SILICONE; STEROID; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN;

BASEMENT MEMBRANE; DATA BASE; DIABETIC RETINOPATHY; ENDOPHTHALMITIS; ENDOTHELIUM CELL; FOLLOW UP; GEOGRAPHIC ATROPHY; HUMAN; KNOWLEDGE; MEDLINE; MONOTHERAPY; OPTICAL COHERENCE TOMOGRAPHY; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOGENESIS; PHOTODYNAMIC THERAPY; PIGMENT EPITHELIUM; PROTON RADIATION; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RETINA MACULA AGE RELATED DEGENERATION; RETINAL THICKNESS; REVIEW; THERAPY; THROMBOCYTE AGGREGATION; VISUAL ACUITY; VISUAL IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BLINDNESS; COMBINED MODALITY THERAPY; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MACULAR DEGENERATION; OPHTHALMOLOGY; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISION, LOW;

EID: 84883740525     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318271f265     Document Type: Review

References (160)

1. Holloway TB, Verhoeff FH. Disc-like degeneration of the macula with microscopic report concerning a rumor-like mass in the macular region. Trans Am Ophthalmol Soc 1928;26: 206-228.
2. Smith AF. The growing importance of pharmacoeconomics: the case of age-related macular degeneration. Br J Ophthalmol 2010;94:1116-1117.
3. Foster WJ, TufailW, Issa AM. The quality of pharmacoeconomic evaluations of age-related macular degeneration therapeutics: a systematic review and quantitative appraisal of the evidence. Br J Ophthalmol 2010;94:1118-1126.
4. Buhrmann RHW, Gold D, National Coalition on Vision Health. Forecasting the vision loss epidemic in Canada: current and projected estimates of age-related eye disease: interim summary tables prepared for the National Coalition on Vision Health. Available at: http://www.visionhealth. ca/index.htm. Accessed July 5, 2011.
5. Loewenstein A. The significance of early detection of agerelated macular degeneration: Richard & Hinda Rosenthal Foundation Lecture, The Macula Society 29th Annual Meeting. Retina 2007;27:873-878.
6. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2010;94:2-13.
7. Schmucker C, Loke YK, Ehlken C, et al. Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review. Br J Ophthalmol 2011;95:308-317.
8. Kellner U, Kellner S, Weinitz S. Fundus autofluorescence (488 NM) and near-infrared autofluorescence (787 NM) visualize different retinal pigment epithelium alterations in patients with age-related macular degeneration. Retina 2010;30:6-15.
9. Harding SP. Neovascular age-related macular degeneration: decision making and optimal management. Eye (Lond) 2010; 24:497-505.
10. Munoz B, West SK, Rubin GS, et al. Causes of blindness and visual impairment in a population of older Americans: the Salisbury Eye Evaluation Study. Arch Ophthalmol 2000; 118:819-825.
11. Mata NL, Vogel R. Pharmacologic treatment of atrophic agerelated macular degeneration. Curr Opin Ophthalmol 2010; 21:190-196.
12. Mousa SA, Mousa SS. Current status of vascular endothelial growth factor inhibition in age-related macular degeneration. BioDrugs 2010;24:183-194.
13. Velez-Montoya R, Clapp C, Rivera JC, et al. Intraocular and systemic levels of vascular endothelial growth factor in advanced cases of retinopathy of prematurity. Clin Ophthalmol 2010;4:947-953.
14. Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991; 266:11947-11954.
15. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for agerelated cataract and vision loss: AREDS report no. 9. Arch Ophthalmol 2001;119:1439-1452.
16. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119:1417-1436.
17. Chew EY, Lindblad AS, Clemons T. Summary results and recommendations from the age-related eye disease study. Arch Ophthalmol 2009;127:1678-1679.
18. Dugel P. Sirolimus in the treatment of retinal diseases. mTOR inhibitors: a new class of therapeutics. Retina Today 2009; 4:38-41.
19. Dutcher JP. Mammalian target of rapamycin inhibition. Clin Cancer Res 2004;10:6382S-6387S.
20. Ni Z, Hui P. Emerging pharmacologic therapies for wet agerelated macular degeneration. Ophthalmologica 2009;223: 401-410.
21. National Eye Institute (NEI). Pilot study of the evaluation of subconjunctival sirolimus in the treatment of bilateral geographic atrophy associated with age-related macular degeneration. Available at: http://clinicaltrials.gov/ct2/show/NCT00766649. Accessed July 5, 2011. Clinical Trials: NCT00766649.
22. National Eye Institute (NEI). Treatment of choroidal subretinal neovascularization with agents directed against the immune response. Available at: http://clinicaltrials.gov/ct2/show/NCT00304954. Accessed July 8, 2011. ClinicalTrials. gov: NCT00304954.
23. Zarbin MA, Rosenfeld PJ. Pathway-based therapies for agerelated macular degeneration: an integrated survey of emerging treatment alternatives. Retina 2010;30:1350-1367.
24. Alimera Sciences. A randomized, double-masked, felloweye comparison of the safety and efficacy of 0.2 and 0.5 mg/day fluocinolone acetonide intravitreal insert to sham injection in subjects with bilateral geographic atrophy due to AMD. Available at: http://clinicaltrials.gov/ct2/show/ NCT00695318. Accessed July 8, 2011. ClinicalTrials.gov: NCT00695318.
25. Ricklin D, Lambris JD. Compstatin: a complement inhibitor on its way to clinical application. Adv Exp Med Biol 2008; 632:273-292.
26. Despriet DD, Klaver CC, Witteman JC, et al. Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration. JAMA 2006;296:301-309.
27. Potentia Pharmaceuticals Inc. Assessment of safety of intravitreal POT-4 therapy for patients with neovascular agerelated macular degeneration (AMD). Available at: http://clinicaltrials.gov/ct2/show/NCT00473928. Accessed 10, July 2011. ClinicalTrials.gov: NCT00473928.
28. Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 2002;134:411-431.
29. Ophthotech Corp. A phase I study of ARC1905 (anti-C5 aptamer) in subjects with dry age-related macular degeneration. Available at: http://clinicaltrials. gov/ct2/show/NCT00950638. ClinicalTrials.gov: NCT00950638. Accessed July 21, 2011.
30. Ophthotech Corp. A phase 1 ascending dose and parallel group trial to establish the safety, tolerability and pharmacokinetic profile of multiple intravitreous injections of ARC1905 (anti-C5 aptamer) given either in combination therapy with multiple doses of Lucentis-0.5 mg/eye, or with one induction dose of Lucentis-0.5 mg/eye in subjects with neovascular age-related macular degeneration. Available at: http://clinicaltrials.gov/ct2/show/ NCT00709527. Accessed July 21, 2011. ClinicalTrials.gov: NCT00709527.
31. University of Miami. Eculizumab for the treatment of nonexudative age-related macular degeneration: an exploratory study to evaluate the effects of C5 inhibition on drusen and geographic atrophy. Available at: http://clinicaltrials.gov/ct2/show/NCT00935883. Accessed July 12, 2011. ClinicalTrials. gov: NCT00935883.
32. MacDonald IM, Sauve Y, Sieving PA. Preventing blindness in retinal disease: ciliary neurotrophic factor intraocular implants. Can J Ophthalmol 2007;42:399-402.
33. Neurotech Pharmaceuticals. A phase II study of implants of encapsulated human NTC-201 cells releasing ciliary neurotrophic factor (CNTF), in participants with visual acuity impairment associated with atrophic macular degeneration. Available at: http://clinicaltrials.gov/ct2/show/NCT00447954. Accessed July 12, 2011. ClinicalTrials.gov: NCT00447954.
34. Alcon Research. Geographic atrophy treatment evaluation (GATE). Available at: http://clinicaltrials.gov/ct2/show/NCT00890097. Accessed July 21, 2011. ClinicalTrials. gov: NCT00890097.
35. Schmitz-Valckenberg S, Bindewald-Wittich A, Dolar-Szczasny J, et al. Correlation between the area of increased autofluorescence surrounding geographic atrophy and disease progression in patients with AMD. Invest Ophthalmol Vis Sci 2006;47:2648-2654.
36. Schmitz-Valckenberg S, Bultmann S, Dreyhaupt J, et al. Fundus autofluorescence and fundus perimetry in the junctional zone of geographic atrophy in patients with age-related macular degeneration. Invest Ophthalmol Vis Sci 2004;45: 4470-4476.
37. Katz ML, Robison WG Jr. What is lipofuscin? Defining characteristics and differentiation from other autofluorescent lysosomal storage bodies. Arch Gerontol Geriatr 2002;34: 169-184.
38. Radu RA, Han Y, Bui TV, et al. Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscin-based retinal diseases. Invest Ophthalmol Vis Sci 2005;46:4393-4401.
39. Acucela Inc. Study of the safety, tolerability, pharmacokinetics and pharmacodynamics of ACU-4429 in subjects with geographic atrophy. Available at: http://clinicaltrials.gov/ct2/show/NCT01002950. Accessed July 2011. ClinicalTrials. gov: NCT01002950.
40. Sirion Therapeutics Inc. A phase II multicenter, randomized, double-masked, placebo-controlled, dose-comparison study of the safety and efficacy of fenretinide in the treatment of geographic atrophy in subjects with age-related macular degeneration. Available at: http://clinicaltrials.gov/ct2/ show/NCT00429936. Accessed July 28, 2011. ClinicalTrials. gov: NCT00429936.
41. Radu RA, Mata NL, Nusinowitz S, et al. Isotretinoin treatment inhibits lipofuscin accumulation in a mouse model of recessive Stargardt's macular degeneration. Novartis Found Symp 2004;255:51-63; discussion 63-57, 177-178.
42. Grunwald JE, Metelitsina TI, Dupont JC, et al. Reduced foveolar choroidal blood flow in eyes with increasing AMD severity. Invest Ophthalmol Vis Sci 2005;46:1033-1038.
43. UCB Inc. Confirmatory, prospective, randomized, doubleblind, placebo-controlled, parallel groups study to assess the efficacy and safety of prostaglandin E1 in subjects with dry age-related macular degeneration. Available at: http://clinicaltrials. gov/ct2/show/NCT00619229. Accessed July 21, 2011. ClinicalTrials.gov: NCT00619229.
44. MacuCLEAR Inc. A pilot, single-center, open-label study of the safety of MC-1101 in both normal volunteers and patients with early non-exudative age-related macular degeneration. Available at: http://clinicaltrials.gov/ct2/ show/NCT01013376. Accessed July 28, 2011. ClinicalTrials.gov: NCT01013376.
45. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
46. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
47. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular agerelated macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43-58.e41.
48. Rothenbuehler SP, Waeber D, Brinkmann CK, et al. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. Am J Ophthalmol 2009;147:831-837.
49. Steinbrook R. The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 2006;355:1409-1412.
50. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular agerelated macular degeneration: PIER study year 2. Am J Ophthalmol 2010;150:315-324.e311.
51. Choi DY, Ortube MC, McCannel CA, et al. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib. Retina 2011;31: 1028-1035.
52. Bakri SJ, Pulido JS, McCannel CA, et al. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye (Lond) 2009; 23:181-185.
53. Gismondi M, Salati C, Salvetat ML, et al. Short-term effect of intravitreal injection of ranibizumab (Lucentis) on intraocular pressure. J Glaucoma 2009;18:658-661.
54. Adelman RA, Zheng Q, Mayer HR. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther 2010;26:105-110.
55. Bakri SJ, McCannel CA, Edwards AO, Moshfeghi DM. Persistent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol 2008;246: 955-958.
56. Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 2011;95:1111-1114.
57. Seth RK, Salim S, Shields MB, Adelman RA. Assessment of optic nerve cup-to-disk ratio changes in patients receiving multiple intravitreal injections of antivascular endothelial growth factor agents. Retina 2009;29:956-959.
58. Singer MA, Awh CC, Sadda S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2012;119:1175-1183.
59. Sondell M, Lundborg G, Kanje M. Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J Neurosci 1999;19: 5731-5740.
60. Storkebaum E, Lambrechts D, Carmeliet P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 2004;26:943-954.
61. Nishijima K, Ng YS, Zhong L, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007;171:53-67.
62. Horsley MB, Mandava N, Maycotte MA, Kahook MY. Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy. Am J Ophthalmol 2010;150:558-561.e551.
63. Rosenfeld PJ, Shapiro H, Tuomi L, et al. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology 2011; 118:523-530.
64. Mariani A, Deli A, Ambresin A, Mantel I. Characteristics of eyes with secondary loss of visual acuity receiving variable dosing ranibizumab for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2011;249:1635-1642.
65. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-1908.
66. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119: 1388-1398.
67. Quiroz-Mercado H, Velez-Montoya R, Fromow-Guerra J, et al. Mexican clinical experience in ocular anti-angiogenic therapy [in Spanish]. Gac Med Mex 2008;144:245-253.
68. Gordon-Angelozzi M, Velez-Montoya R, Fromow-Guerra J, et al. Bevacizumab local complications. Ophthalmology 2009;116:2264.e1-e3.
69. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 2007;12:713-718.
70. Hahn R, Sacu S, Michels S, et al. Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age-related macula degeneration [in German]. Ophthalmologe 2007;104:588-593.
71. Weigert G, Michels S, Sacu S, et al. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. Br J Ophthalmol 2008;92:356-360.
72. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci 2006;47:4569-4578.
73. Wu L, Fernando Arevalo J, Maia M, et al. Comparing outcomes in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration treated with two different doses of primary intravitreal bevacizumab: results of the Pan-American Collaborative Retina Study Group (PACORES) at the 12-month follow-up. Jpn J Ophthalmol 2009;53:125-130.
74. Jyothi S, Chowdhury H, Elagouz M, Sivaprasad S. Intravitreal bevacizumab (Avastin) for age-related macular degeneration: a critical analysis of literature. Eye (Lond) 2010;24:816-824.
75. Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005;46:726-733.
76. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007; 114:2179-2182.
77. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114:855-859.
78. Kahook MY, Kimura AE, Wong LJ, et al. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging 2009;40:293-295.
79. Liu L, Ammar DA, Ross LA, et al. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling. Invest Ophthalmol Vis Sci 2011;52:1023-1034.
80. Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399-1411.
81. Sato T, Emi K, Ikeda T, et al. Severe intraocular inflammation after intravitreal injection of bevacizumab. Ophthalmology 2010;117:512-516.e511-e512.
82. Yamashiro K, Tsujikawa A, Miyamoto K, et al. Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch. Retina 2010;30:485-490.
83. Wickremasinghe SS, Michalova K, Gilhotra J, et al. Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology 2008;115:1911-1915.
84. Mason JO III, White MF, Feist RM, et al. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina 2008;28:564-567.
85. McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina 2011;31:654-661.
86. Yenerel NM, Dinc UA, Gorgun E. A case of sterile endophthalmitis after repeated intravitreal bevacizumab injection. J Ocul Pharmacol Ther 2008;24:362-363.
87. Sun X, Xu X, Zhang X. Counterfeit bevacizumab and endophthalmitis. N Engl J Med 2011;365:378-379; author reply 379.
88. Cheng JW, Wei RL. Ranibizumab for age-related macular degeneration. N Engl J Med 2011;364:582.
89. Pollack A. Five More Reports of Avastin Injections Causing Blindness. The New York Times. September 1, 2011. Available at: http://www.nytimes.com/2011/ 09/02/business/more-reportsof-avastin-causing-blindness.html. Accessed January 30, 2012.
90. Dixon JA, Oliver SC, Olson JL, Mandava N. VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs 2009;18:1573-1580.
91. Brown DM, Heier JS, Ciulla T, et al. Primary endpoint results of a phase II study of vascular endothelial growth factor trapeye in wet age-related macular degeneration. Ophthalmology 2011;118:1089-1097.
92. Nguyen QD, Shah SM, Browning DJ, et al. A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology 2009;116:2141-2148.e2141.
93. Regeneron Pharmaceuticals. A randomized, double masked, active controlled phase III study of the efficacy, safety, and tolerability of repeated doses of intravitreal VEGF trap in subjects with neovascular age-related macular degeneration. Available at: http://clinicaltrials.gov/ct2/show/NCT00509795. Accessed January 9, 2012. ClinicalTrials.gov: NCT00509795.
94. Bayer. A randomized, double masked, active controlled, phase 3 study of the efficacy, safety, and tolerability of repeated doses of intravitreal VEGF trap in subjects with neovascular age-related macular degeneration (AMD). Available at: http://clinicaltrials.gov/ct2/show/NCT00637377. Accessed February 6, 2012. ClinicalTrials.gov: NCT00637377.
95. Regeneron Pharmaceuticals. An open-label, long-term, safety and tolerability study of intravitreal VEGF Trap-Eye in neovascular age-related macular degeneration. Available at: http://clinicaltrials.gov/ct2/show/ NCT00964795. Accessed July 21, 2011. ClinicalTrials.gov: NCT00964795.
96. Regeneron Pharmaceuticals Inc and Bayer HealthCare. Two year results of phase 3 studies with EYLEA™(aflibercept) injection in wet AMD show sustained improvement in visual acuity. Available at: http://newsroom.regeneron. com/releasedetail.cfm? releaseid=629800. Published 2011. Accessed January 19, 2012.
97. Ratner M. Eylea approval transforms Regeneron. Nat Biotechnol 2012;30:4.
98. Spaide RF. Rationale for combination therapies for choroidal neovascularization. Am J Ophthalmol 2006;141:149-156.
99. Spaide RF. Rationale for combination therapy in age-related macular degeneration. Retina 2009;29:S5-S7.
100. Kim HW, Kim JL, Lee MH, et al. Combined treatment of photodynamic therapy and bevacizumab for choroidal neovascularization secondary to age-related macular degeneration. Korean J Ophthalmol 2011;25:231-237.
101. Lopez PF, Grossniklaus HE, Lambert HM, et al. Pathologic features of surgically excised subretinal neovascular membranes in age-related macular degeneration. Am J Ophthalmol 1991;112:647-656.
102. Zambarakji HJ, Lane AM, Ezra E, et al. Proton beam irradiation for neovascular age-related macular degeneration. Ophthalmology 2006;113:2012-2019.
103. Evans JR, Sivagnanavel V, Chong V. Radiotherapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2010 May 12;(5):CD004004.
104. Sivagnanavel V, Evans JR, Ockrim Z, Chong V. Radiotherapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2004 Oct 18;(4):CD004004.
105. Chakravarthy U, Houston RF, Archer DB. Treatment of agerelated subfoveal neovascular membranes by teletherapy: a pilot study. Br J Ophthalmol 1993;77:265-273.
106. Brady LW, Freire JE, Longton WA, et al. Radiation therapy for macular degeneration: technical considerations and preliminary results. Int J Radiat Oncol Biol Phys 1997;39: 945-948.
107. Hart PM, Chakravarthy U, MacKenzie G, et al. Teletherapy for subfoveal choroidal neovascularisation of age-related macular degeneration: results of follow up in a non-randomised study. Br J Ophthalmol 1996;80:1046-1050.
108. Spaide RF, Guyer DR, McCormick B, et al. External beam radiation therapy for choroidal neovascularization. Ophthalmology 1998;105:24-30.
109. Valmaggia C, Ries G, Ballinari PA. 5-year follow-up study for distance visual acuity after low dose radiation on subfoveal choroidal neovascularization in age-related macular degeneration. Doc Ophthalmol 2001;103:201-209.
110. Park SS, Daftari I, Phillips T, Morse LS. Three-year followup of a pilot study of ranibizumab combined with proton beam irradiation as treatment for exudative age-related macular degeneration. Retina 2012;32:956-966.
111. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-583.
112. Aras C, Arici C, Akar S, et al. Peeling of internal limiting membrane during vitrectomy for complicated retinal detachment prevents epimacular membrane formation. Graefes Arch Clin Exp Ophthalmol 2009;247:619-623.
113. Avila MP, Farah ME, Santos A, et al. Twelve-month safety and visual acuity results from a feasibility study of intraocular, epiretinal radiation therapy for the treatment of subfoveal CNV secondary to AMD. Retina 2009;29:157-169.
114. Jackson TL, Kirkpatrick L, Tang G, Prasad S. Cost analysis comparing adjuvant epimacular brachytherapy with anti-VEGF monotherapy for the management of neovascular age-related macular degeneration. Eye (Lond) 2012;26:557-563.
115. NeoVista Inc. A study of strontium90 beta radiation with Lucentis to treat age-related macular degeneration (CABERNET). Available at: http://clinicaltrials.gov/ct2/show/NCT00454389. Accessed January 31, 2012. ClinicalTrials.gov: NCT00454389.
116. Retina Today. CABERNET study did not meet primary endpoint at 2 years. Available at: http://enews.bmctoday.net/retinatoday/2012-02.html#1. Published 2012. Accessed July 4, 2012.
117. Moshfeghi AA, Canton VM, Quiroz-Mercado H, et al. 16-Gy low-voltage X-ray irradiation followed by as-needed ranibizumab therapy for AMD: 6-month outcomes of a "radiation-first" strategy. Ophthalmic Surg Lasers Imaging 2011;42:460-467.
118. Canton VM, Quiroz-Mercado H, Velez-Montoya R, et al. 16-Gy low-voltage X-ray irradiation with ranibizumab therapy for AMD: 6-month safety and functional outcomes. Ophthalmic Surg Lasers Imaging 2011;42:468-473.
119. Barakat MR, Shusterman M, Moshfeghi D, et al. Pilot study of the delivery of microcollimated pars plana external beam radiation in porcine eyes. Arch Ophthalmol 2011;129:628-632.
120. Moshfeghi DM, Kaiser PK, Gertner M. Stereotactic low-voltage X-ray irradiation for age-related macular degeneration. Br J Ophthalmol 2011;95:185-188.
121. Hanlon J, Lee C, Chell E, et al. Kilovoltage stereotactic radiosurgery for age-related macular degeneration: assessment of optic nerve dose and patient effective dose. Med Phys 2009; 36:3671-3681.
122. Canton VM, Quiroz-Mercado H, Velez-Montoya R, et al. 24-Gy low-voltage X-ray irradiation with ranibizumab therapy for neovascular AMD: 6-month safety and functional outcomes. Ophthalmic Surg Lasers Imaging 2012;43:20-24.
123. Oraya Therapeutics Inc. INTREPID-IRay plus anti-VEGF treatment for patients with wet AMD. Available at: http://clinicaltrials. gov/ct2/show/ NCT01016873. Published 2012. Accessed January 31, 2012. ClinicalTrials.gov: NCT01016873.
124. Oraya Therapeutics Inc. Oraya therapeutics achieves successful INTREPID study outcomes with a non-invasive radiation therapy for wet AMD. Available at: http://www.orayainc. com/wp-content/uploads/2012/05/Oraya-INTREPID-Press- Release.pdf. Published 2012. Accessed July 5, 2012.
125. Couch SM, Bakri SJ. Review of combination therapies for neovascular age-related macular degeneration. Semin Ophthalmol 2011;26:114-120.
126. Chaudhary V, Mao A, Hooper PL, Sheidow TG. Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration: a prospective randomized trial. Ophthalmology 2007;114:2183-2189.
127. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999; 117:1329-1345.
128. Vallance JH, Johnson B, Majid MA, et al. A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. Eye (Lond) 2010;24:1561-1567.
129. Shah GK, Sang DN, Hughes MS. Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration. Retina 2009;29:133-148.
130. Schmidt-Erfurth UM, Michels S. Changes in confocal indocyanine green angiography through two years after photodynamic therapy with verteporfin. Ophthalmology 2003;110: 1306-1314.
131. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65.e55.
132. Antoszyk AN, Tuomi L, Chung CY, Singh A. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 2008;145:862-874.
133. Spielberg L, Leys A. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years. Graefes Arch Clin Exp Ophthalmol 2010;248:943-956.
134. Schmidt-Erfurth U, Wolf S. Same-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularisation due to age-related macular degeneration. Br J Ophthalmol 2008;92:1628-1635.
135. QLT Inc. QLT announces 12-month results from Novartis sponsored MONT BLANC study evaluating standard-fluence Visudyne-combination therapy. Available at: http://www. qltinc.com/newsCenter/2009/090615.htm. Published 2009. Accessed February 1, 2012.
136. QLT Inc. Final results from Visudyne phase IIIb DENALI study presented at World Ophthalmology Congress. Available at: http://www.news-medical.net/news/ 20100616/Final-resultsfrom-Visudyne-Phase-IIIb-DENALI-study-presented-at-World- Ophthalmology-Congress.aspx. Published 2010. Accessed February 1, 2012.
137. Penfold PL, Wong JG, Gyory J, Billson FA. Effects of triamcinolone acetonide on microglial morphology and quantitative expression of MHC-II in exudative age-related macular degeneration. Clin Experiment Ophthalmol 2001;29:188-192.
138. Edelman JL, Lutz D, Castro MR. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of bloodretinal and blood-aqueous barrier breakdown. Exp Eye Res 2005;80:249-258.
139. Antoszyk AN, Gottlieb JL, Machemer R, Hatchell DL. The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization. Graefes Arch Clin Exp Ophthalmol 1993;231:34-40.
140. Fischer S, Renz D, Schaper W, Karliczek GF. In vitro effects of dexamethasone on hypoxia-induced hyperpermeability and expression of vascular endothelial growth factor. Eur J Pharmacol 2001;411:231-243.
141. Do DV. Antiangiogenic approaches to age-related macular degeneration in the future. Ophthalmology 2009;116:S24-S26.
142. QLT Inc. Reduced fluence Visudyne-anti-VEGF-dexamethasone in combination for AMD lesions (RADICAL). Available at: http://clinicaltrials.gov/ct2/show/ NCT00492284. Updated May 31, 2011. Accessed February 1, 2013. ClinicalTrials.gov: NCT00492284.
143. Chaoran Z, Zhirong L, Gezhi X. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves the antiangiogenic efficacy for advanced stage mouse corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2011;249:1493-1501.
144. Perez-Santonja JJ, Campos-Mollo E, Lledo-Riquelme M, et al. Inhibition of corneal neovascularization by topical bevacizumab (anti-VEGF) and Sunitinib (anti-VEGF and anti-PDGF) in an animal model. Am J Ophthalmol 2010;150: 519-528.e511.
145. Weisshardt P, Trarbach T, Durig J, et al. Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab. Histochem Cell Biol 2012;137:391-401.
146. Cursiefen C, Chen L, Borges LP, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 2004;113:1040-1050.
147. Bergers G, Song S, Meyer-Morse N, et al. Benefits of targeting both pericytes and endothelial cells in the tumor vascula-ture with kinase inhibitors. J Clin Invest 2003;111: 1287-1295.
148. Jain RK, Booth MF. What brings pericytes to tumor vessels? J Clin Invest 2003;112:1134-1136.
149. Jo N, Mailhos C, Ju M, et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of antivascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 2006;168:2036-2053.
150. Gee MS, Procopio WN, Makonnen S, et al. Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Am J Pathol 2003;162:183-193.
151. Helfrich I, Scheffrahn I, Bartling S, et al. Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J Exp Med 2010;207:491-503.
152. Roskoski R Jr. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun 2007;356:323-328.
153. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a
154. Takahashi H, Obata R, Tamaki Y. A novel vascular endothelial growth factor receptor 2 inhibitor, SU11248, suppresses choroidal neovascularization in vivo. J Ocul Pharmacol Ther 2006;22:213-218.
155. Ophthotech Corp. A phase 1, safety, tolerability and pharmacokinetic profile of intravitreous injections of E10030 (anti-PDGF pegylated aptamer) in subjects with neovascular age-related macular degeneration. Available at: http://clinicaltrials.gov/ct2/show/NCT00569140. Updated January 21, 2010. Accessed January 30, 2012. Clinical Trials.gov: NCT00569140.
156. Ophthotech Corp. A safety and efficacy study of E10030 (anti-PDGF pegylated aptamer) plus Lucentis for neovascular agerelated macular degeneration. Available at: http://clinicaltrials. gov/ct2/show/NCT01089517. Accessed January 25, 2012. Clinical Trials.gov: NCT01089517.
157. Keane PA, Sadda SR. Development of anti-VEGF therapies for intraocular use: a guide for clinicians. J Ophthalmol 2012; 2012:483034.
158. Hosseini H, Nowroozzadeh MH, Salouti R, Nejabat M. Anti-VEGF therapy with bevacizumab for anterior segment eye disease. Cornea 2012;31:322-334.
159. Kimoto K, Kubota T. Anti-VEGF agents for ocular angiogenesis and vascular permeability. J Ophthalmol 2012;2012: 852183.
160. Davis J, Olsen TW, Stewart M, Sternberg P Jr. How the comparison of age-related macular degeneration treatments trial results will impact clinical care. Am J Ophthalmol 2011;152:509-514.